ALT - Altimmune Inc logo

Altimmune Inc

ALT

Altimmune Inc develops peptide-based therapeutics targeting serious liver diseases and obesity. Its lead candidate, pemvidutide, is in Phase 3 trials for metabolic dysfunction-associated steatohepatitis and alcohol-related liver diseases.

βš•οΈ Healthcare NASDAQ Listed 2005 $ USD
$1,000 invested 5 years ago β†’$233today

Score Overview

1 Year
Score
Net Growth-4.16%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growth-24.39%
Rev TrendShrank
Revenue Consistencyβ€”
5 Years
Score3.4
Net Growth5.49%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth-99.30%
Rev Trend40%
Revenue Consistencyβ€”
10 Years
Score
Net Growth-147.33%
Net Trend40%
Net Income Consistency
Rev Growth-99.41%
Rev Trend38%
Revenue Consistency
20 Years
Score2.3
Net Growth-90x
Net Trend45%
Net Income Consistency
Rev Growth-98.32%
Rev Trend44%
Revenue Consistency
All Time
Score
Net Growth-330x
Net Trend48%
Net Income Consistency
Rev Growth-94.71%
Rev Trend47%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Altimmune Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • ALT

2016: 92.2% Β· 2021: 77.7% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 2.97β€”
1 Year2025-09-29
$ 3.79-21.64%
5 Years2021-09-29
$ 12.76-76.72%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 31K-$ 91M$ 326M
2025$ 41K-$ 88M$ 273M
2024$ 20K-$ 95M$ 131M
2023$ 426K-$ 88M$ 197M
2022-$ 68K-$ 84M$ 184M
2021$ 4M-$ 97M$ 190M
2020$ 8M-$ 49M$ 215M
2019$ 5M-$ 20M$ 37M
2018$ 10M-$ 39M$ 33M
2017-$ 46M$ 8M
2016$ 5M$ 193M$ 220M
2015$ 10M-$ 3M$ 15M
2014$ 10M-$ 9M$ 18M
2013$ 17M-$ 11M$ 10M
2012$ 25M-$ 4M$ 12M
2011$ 24M-$ 3M$ 11M
2010$ 20M-$ 34M$ 11M
2009$ 27M-$ 32M$ 5M
2008$ 32M-$ 36M$ 22M
2007$ 14M-$ 13M$ 52M
2006$ 1M$ 1M$ 675.3K
IPO2005$ 586.07K$ 277.3K$ 1M
ALT - Altimmune Inc logo

Altimmune Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 8M to $ 41K and net income went from -$ 49M to -$ 88M. Revenue increased in 2 of those 5 years; net income in 2.

Between 2015 and 2025, revenue declined from $ 10M to $ 41K and net income went from -$ 3M to -$ 88M. Revenue increased in 4 of those 10 years; net income in 4.

Altimmune Inc currently holds a 20-year HDB Score of 2.3 out of 10. How the HDB Score is calculated.

Membership

Continue ALT’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies